BI 425809
- Health
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia
Ingelheim, Germany: Results presented at the 33rd ECNP Congress from a 12-week, placebo-controlled Phase II trial demonstrated BI 425809 has…
Read More »